Transcodent, headquartered in Kiel, Germany, is expected to achieve revenues of EUR 17 million in 2017. The company generates the majority of its revenues in Europe and the Americas, and manufactures in Kiel. Transcodent is known for its multiple dose and unit dose application systems with highest barrier properties and a wide range of premium-quality needles. It also offers the development and manufacturing of customer-specific injectionmolded application systems. Transcodent branded products are used by dentists in anesthetics, endo irrigation, prevention and aesthetic restoration.

The proposed transaction allows Sulzer to round out its dental portfolio with fine needles, unit doses, contract filling and customized assembly. Combining the complementary product portfolios enables Sulzer to become a full-line supplier in dental applications and to generate significant revenue synergies by leveraging scale and cross-selling opportunities.

Transcodent is Sulzer’s fourth Applicator Systems acquisition over the last 18 months. Its current management team has agreed to join Sulzer to continue to develop the dental segment.

Including synergies, Sulzer pays an EV/EBITDA multiple below 10x. The transaction is expected to close in the third quarter of 2017, subject to customary conditions.

Media contact

Media Relations

Domenico Truncellito

Group Head of External Communications

Sulzer Management Ltd

Neuwiesenstrasse 15


Investor Relations

Thomas Zickler

Chief Financial Officer

Sulzer Management Ltd

Neuwiesenstrasse 15

8401 Winterthur


News release

Contact us